TACE联合索拉非尼治疗中晚期肝细胞癌的安全性和临床疗效研究

目的 探讨经导管肝动脉化疗栓塞(TACE)联合索拉非尼治疗中晚期肝细胞癌的安全性和临床疗效. 方法 整群选择该医院2010年2月—2013年8月间收治的86例中晚期肝细胞癌患者作为研究对象,随机分为观察组和对照组,每组43例. 对照组进行TACE,观察组在此基础行联合口服索菲拉尼,比较两组患者治疗效果和安全性. 结果 观察组疾病控制率为46.51%高于对照组25.58%(P<0.05);观察组发生腹泻、高血压、手足皮肤反应等21例,发生率为48.84%,对照组发生不良反应19例,发生率为44.19%,差异无统计学意义(P>0.05);观察组总体生存率、半年生存率、1年生存率均明显高于对照组 (P<0.05). 结论 TACE联合索拉非尼治疗中晚期肝细胞癌的是一种可行的治疗方式,治疗效果较好,疾病控制率达到46.51%,多数患者肿瘤生长得到控制,生存期得到延长,且耐受较好,值得临床推广和应用.

Research on the Security and Clinical Curative Effect of TACE Combined with Sorafenib in the Treatment of Hepatocellular Carcinoma in the Middle and Late Period

Objective To discuss the security and clinical curative effect of TACE combined with sorafenib in the treatment of hepatocellular carcinoma in the middle and late period. Methods 86 cases of patients with hepatocellular carcinoma in the middle and late period treated in the hospital from February 2010 to August 2013 were selected as the research objects and randomly divided into observation group and control group with 43 cases in each, the control group were given TACE, the observation group were given TACE combined with sorafenib, the treatment effects and security of the two groups were compared. Results The disease control rate in the observation group was 46.51%, which was higher than that (25.58%) in the control group (P<0.05),diarrhea, hypertension and hand foot skin reaction occurred to 21 cases in the observation group and the incidence rate was 48.84%, adverse reactions occurred to 19 cases in the control group and the incidence rate was 44.19%, the difference was not obvious (P>0.05), the overall survival rate, half-year survival rate and 1-year survival rate in the observation group were obviously higher than those in the control group (P<0.05). Conclusion TACE combined with sorafenib in the treatment of hepatocellular carcinoma in the middle and late period is a feasible treatment method with a better treatment effect, the disease control rate is as high as 46.51%, tumor growth of most patients can be controlled and patients' survival period can be prolonged and it is well tolerated, which is worthy of promotion and application in clinic.